- Home
- CYN vs AYTU Comparison
CYN vs AYTU Comparison
Compare CYN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- AYTU
- Stock Information
- Founded
- CYN 2013
- AYTU N/A
- Country
- CYN United States
- AYTU United States
- Employees
- CYN N/A
- AYTU N/A
- Industry
- CYN EDP Services
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- AYTU Health Care
- Exchange
- CYN Nasdaq
- AYTU Nasdaq
- Market Cap
- CYN 9.3M
- AYTU 10.7M
- IPO Year
- CYN 2021
- AYTU N/A
- Fundamental
- Price
- CYN $6.53
- AYTU $1.51
- Analyst Decision
- CYN
- AYTU
- Analyst Count
- CYN 0
- AYTU 0
- Target Price
- CYN N/A
- AYTU N/A
- AVG Volume (30 Days)
- CYN 1.8M
- AYTU 45.2K
- Earning Date
- CYN 11-06-2024
- AYTU 11-13-2024
- Dividend Yield
- CYN N/A
- AYTU N/A
- EPS Growth
- CYN N/A
- AYTU N/A
- EPS
- CYN N/A
- AYTU N/A
- Revenue
- CYN $102,118.00
- AYTU $79,759,000.00
- Revenue This Year
- CYN $18.11
- AYTU N/A
- Revenue Next Year
- CYN $418.19
- AYTU $2.35
- P/E Ratio
- CYN N/A
- AYTU N/A
- Revenue Growth
- CYN N/A
- AYTU N/A
- 52 Week Low
- CYN $2.85
- AYTU $1.41
- 52 Week High
- CYN $59.50
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- CYN 67.15
- AYTU 26.32
- Support Level
- CYN $5.64
- AYTU $1.41
- Resistance Level
- CYN $8.75
- AYTU $1.63
- Average True Range (ATR)
- CYN 0.88
- AYTU 0.21
- MACD
- CYN 0.16
- AYTU -0.01
- Stochastic Oscillator
- CYN 58.43
- AYTU 11.98
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.